Goldfinch Bio
Edit

Goldfinch Bio

https://www.goldfinchbio.com/
Last activity: 08.06.2021
Active
Categories: BioTechContentHealthTechInformationMediaMedTechPageProductSocialTime
Page Transparency
Goldfinch Bio, Inc. is responsible for this page.

Page Manager Location
United States

About

Goldfinch Bio’s Facebook page is intended only for residents of the United States and its territories.

Goldfinch Bio is a privately held biotechnology company advancing kidney precision medicines. With our sole focus on kidney diseases, Goldfinch Bio aspires to be the world’s leading precision medicine kidney company. Our mission is to deliver disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. Our vision is to save kidneys and end dialysis.

There are few therapeutic options that target the underlying cause of disease. Our solution to address this growing need is applying precision medicine to pioneer the discovery, development, and commercialization of kidney disease treatments.

Pioneering Precision Medicine for People with Kidney Diseases

Historically, there has been a ‘one size fits all’ approach to treating kidney disease. This has been due to the lack of understanding of kidney disease at the molecular level. Thanks to a growing understanding of kidney biology and genetics, including pioneering research by the founders of Goldfinch, the scientific community is starting to understand the heterogeneity inherent in kidney diseases.

Our precision medicine product engine is the foundation of our approach. Our product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse patient populations to identify patient subsets most likely to respond to our treatment.

Precision Medicine Product Candidates We Are Currently Investigating

We currently do not have any products approved by the U.S. Food and Drug Administration. We have a pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical need. We are developing our lead investigational precision medicine product candidate, GFB-887, as a therapy for Focal Segmental Glomerulosclerosis (FSGS). FSGS is a rare disease that attacks the kidney's glomerulus and podocytes, causing scarring that leads to permanent kidney damage.

For complete information on Goldfinch Bio’s guidelines, policies, and terms of use, please click the links below:

Privacy Policy: https://www.goldfinchbio.com/privacy-policy/
Terms of Use: https://www.goldfinchbio.com/terms-of-use/
To review Facebook’s Community Standards, please visit the following webpage: https://www.facebook.com/communitystandards

Community Guidelines

Thank you for your interest in Goldfinch Bio. Our Facebook page and other social media sites enable us to engage and communicate with people living with kidney disease and their families and loved ones, advocates, scientists, healthcare providers and others who are interested in learning more about our activities to pioneer precision-based kidney medicines and to raise awareness about kidney disease. We use social media as part of our commitment to transparency and to provide information and content about our company to various stakeholders within the broader kidney community, and foster open and constructive dialogue on a range of kidney-related topics.

We have a presence on several social media platforms that you can access to keep up to date with Goldfinch Bio news and activities. These accounts are subject to our community guidelines, which can be reviewed below.

We encourage you to engage by following us and discussing relevant topics. However, Goldfinch Bio expects that followers will be respectful of others. Please read through these simple rules, and check back from time to time because they may change:

1. Due to the unique legal requirements in which we operate, we cannot offer medical advice or otherwise engage in a promotion or discussion about specific investigational product candidates or approved products or treatment options — ours or those of other companies — on our social media sites. Your physician remains your best source of information about medicines and treatments in the United States.
2. The following content is not acceptable and can be subject to deletion, and we reserve the right to block users who violate these terms:
• Content that includes profanity, defamatory, libelous, and offensive or demeaning language (including images, videos, and links)
• Content that is misleading, fraudulent, or deceptive
• Disparaging or threatening comments about others
• Content about specific products or treatment options
• Posts that are excessively repetitive and/or disruptive to the community or are SPAM-like in nature
• Posts containing proprietary, confidential, sensitive, or non-public information about, or related to, Goldfinch Bio or any other person or company, are not acceptable. Similarly, posts related to current or future litigation in which Goldfinch Bio is involved are not acceptable
• Posts that contain links, including those to videos, not owned by Goldfinch Bio
• Posts sharing personal information about you and any connection to Goldfinch Bio
• Posts selling or soliciting consultation, services, or products from an individual or a third party
3. Please keep in mind that Goldfinch Bio does not verify, represent or endorse any opinions or information expressed by third-party organizations or individuals posting content to the Goldfinch Bio social media sites, and that any content posted by anyone other than Goldfinch Bio is the responsibility of the submitter and not Goldfinch Bio.
4. Any comments made by users, including current or former Goldfinch Bio employees, reflect their individual thoughts and positions. These are not endorsed by Goldfinch Bio or representative of Goldfinch Bio as a company.
5. The Goldfinch Bio social media sites are not the places to report any medical adverse events or reactions or investigational product complaints. If you believe that you have experienced any medical adverse events or reactions from a Goldfinch Bio investigational product candidate, please consult your clinical trial site investigator or your physician immediately. If you believe you have experienced an adverse event while enrolled in a Goldfinch Bio clinical trial. Should you accidentally include an adverse event report in your post, Goldfinch Bio may need to contact you to find out more information. This is due to regulatory requirements concerning safety reporting. In the United States, you may also report side effects to the U.S. Food and Drug Administration (FDA) or calling 1-800-FDA-1088.
6. We do not aim to store your social media profile unique ID, email, or other personal details. However, in case of an adverse event or investigational product issue we would need to store information about you, such as your name or location. This information is required to be submitted to your clinical trial site Investigator and/or regulatory authorities.

Medical and health topics may be discussed on Goldfinch Bio social media platforms but should not be construed as medical advice.

We may occasionally share links to third-party sites when we think you will find the information helpful. However, please note that this does not in any way constitute an official endorsement of the individual, site, organization, or company. We are not responsible for the terms and conditions, privacy policy or content of any website accessed through links or references in our social media platforms.

Please note that we may unfollow a user who dramatically changes their mission and objectives, or whom we feel violates our community guidelines.

We want those who follow Goldfinch Bio to feel free to share. However, because our social media profiles are public and anyone can engage with us, we cannot be responsible for views expressed other than our own. Please read at your own risk and know that, while we are listening, we cannot certify or validate the accuracy of statements made by the followers of the Goldfinch Bio social media sites, and opinions expressed by outside users on our social media sites are not representative of the opinions of Goldfinch Bio.

We reserve the right to remove any of our social media sites and its contents at any time. Please check often for updates, as we reserve the right, at our sole discretion, to modify these community guidelines at any time. Your use of our social media platforms indicates your acceptance of any revisions to these terms. Also, while these rules cover most common situations, they cannot anticipate everything. Consequently, Goldfinch Bio may take any actions it deems appropriate to ensure a particular social media site is not disrupted or abused in any way.

In addition to the privacy policy and terms of use of the third-party social media platform, your use of our social media platforms are governed by Goldfinch Bio’s Terms and Conditions of Use and Privacy Policy.
Likes
40
Followers
3.66K
Mentions
14
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Phone: +1 617-337-4200
Total raised: $155M
Founded date: 2016

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
02.07.2020Series B$100M-
16.12.2016Series A$55M-

Mentions in press and media 14

DateTitleDescription
08.06.2021Tech-backed kidney disease management startup Monogram scores $160MPhoto: SCIEPRO/Getty Images
06.10.2020Biotech looking to fight kidney disease launches with $51 millionA Cambridge biotech that’s working on drugs to reverse kidney disease — rather than merely slow its progression ― was unveiled Tuesday after raising $51 million in venture capital. Walden Biosciences was created by Chicago-based ARCH Ventur...
02.07.2020Ally Bridge Portfolio News – Goldfinch Bio Secures $100 Million in Series B FinancingProceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical ...
30.06.2020Goldfinch Bio Secures $100 Million in Series B FinancingGoldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing of an oversubscribed Series B financing, which raised $100 mil...
30.06.2020Goldfinch Bio Secures $100 Million in Series B FinancingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing of an oversubscribed Series...
30.06.2020Gilead-part­nered Goldfinch Bio lands $100M as it piv­ots to clin­i­cal stage biotechA year af­ter land­ing $109 mil­lion in cash for an ear­ly-stage dis­cov­ery deal with Gilead, Goldfinch Bio has scored a sim­i­lar boun­ty from in­vestors, rais­ing $100 mil­lion in the biotech’s first fi­nanc­ing round since its 2016 laun...
22.08.2019Ver­sant-backed Chi­nook gets a $65M launch round for its dis­cov­ery quest in a resur­gent kid­ney fieldVer­sant is once again step­ping off the beat­en track in biotech to see if they can blaze a trail of their own in a field that has looked too thorny to many in­vestors for years. The ven­ture group and their part­ners at Ap­ple Tree are br...
14.12.2018Shinichi Tamu­ra re­claims the throne at So­sei; Jeff Abbey ex­its Ar­gos for No­vadip; Frank Cz­er­wiec is the new CMO at Goldfinch→ Jeff Abbey is jump­ing to the helm of Bel­gium’s No­vadip Bio­sciences af­ter lead­ing Ar­gos Ther­a­peu­tics as pres­i­dent and CEO for the past eight years. Hav­ing led No­vadip’s au­tol­o­gous cell ther­a­py through a Phase I/IIa tri­a...
16.12.2016Goldfinch Bio Raises $55m in Series A FinancingGoldfinch Bio, a Cambridge, MA-based company focused on discovering and developing precision therapies for patients with kidney disease, raised $55m in Series A financing. The round was led by founding investor Third Rock Ventures. Goldfinc...
14.12.2016Goldfinch Bio Launches with $55M Series A CAMBRIDGE, MA, Third Rock Ventures announced Goldfinch Bio was launched with $55 million in Series A financing to translate breakthroughs in genetics and kidney biology. >> Click here for more funding data on Goldfinch Bio >>...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In